Characteristics of patients with any
| Characteristics | RAS/RAF(+) |
RAS/RAF(-) |
|---|---|---|
| Age years, median (range) | 69 (64–82) | 66 (32–80) |
| Gender, male, N (%) | 9 (64%) | 18 (50%) |
| Cytogenetics | ||
| Abnormal | 12 | 19 |
| Complex (≥3) | 10 | 13 |
| ISS stage at diagnosis | ||
| I, N (%) | 0 (0%) | 6 (17%) |
| II, N (%) | 5 (36%) | 11 (31%) |
| III, N (%) | 9 (64%) | 17 (47%) |
| Unknown, N (%) | 2 (6%) | |
| Frontline treatment | ||
| Bortezomib-melphalan-prednisolone with transplant | 2 (14%) | 9 (25%) |
| Bortezomib-melphalan-prednisolone without transplant | 12 (86%) | 24 (67%) |
| Others with transplant | 0 (0%) | 3 (8%) |
| Best response of frontline treatment | ||
| CR or better | 5 (36%) | 18 (50%) |
| VGPR | 4 (29%) | 9 (25%) |
| PR | 5 (36%) | 8 (22%) |
| SD | 0 (0%) | 1 (3%) |
Abbreviations: CR, complete response; PR, partial response; RAS/RAF(+), presence of any
Blood Res 2020;55:159~168 https://doi.org/10.5045/br.2020.2020137
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd